Highlights and Quick Summary
- Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending June 30, 2023 was 12.7% (a -31.39% decrease compared to previous quarter)
- Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -649.78%
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2022 was -2.32% (a -115.6% decrease from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2021 was 14.87% (a 36.42% increase from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 10.9% (a -68.91% decrease from previous year)
- Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending June 30, 2023 was 7.04% (a 570.48% increase compared to previous quarter)
- Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth increased by 491.6% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| 7.04% | 1.05% | -2.32% | 1.19% |
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Selling, General and Administrative (SG&A) Expenses Growth of Emergent Biosolutions Inc.
Most recent Selling, General and Administrative (SG&A) Expenses Growthof EBS including historical data for past 10 years.Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 12.7% | 18.51% | – | – | – |
| 2022 | 0.0% | -2.31% | -11.07% | 4.82% | -2.32% |
| 2021 | 14.74% | 8.74% | 20.0% | 16.07% | 14.87% |
| 2020 | 13.55% | 16.15% | 7.34% | 6.57% | 10.9% |
| 2019 | -10.63% | 54.39% | 79.24% | 63.5% | 35.06% |
| 2018 | 95.51% | 22.02% | 23.95% | 13.8% | 41.71% |
| 2017 | 18.99% | -15.2% | -11.29% | 10.84% | -0.14% |
| 2016 | 42.52% | 57.71% | -1.45% | -8.06% | 18.12% |
| 2015 | 38.18% | -14.83% | 19.3% | 14.64% | 11.56% |
| 2014 | -30.48% | 37.97% | 49.04% | 50.23% | 23.57% |
| 2013 | 30.41% | 14.62% | 14.56% | 2.75% | 15.61% |
| 2012 | 6.69% | 9.88% | – | – | 2.34% |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic